Sign in
II

INSMED Inc (INSM)·Q1 2025 Earnings Summary

Executive Summary

  • ARIKAYCE delivered double‑digit growth: Q1 2025 revenue of $92.8M (+22.9% YoY) with strength in the U.S., Japan, and Europe; FY25 ARIKAYCE revenue guidance reiterated at $405–$425M (11–17% YoY) .
  • Results vs S&P Global consensus: revenue modest beat (actual $92.8M vs $91.25M estimate)* while EPS missed slightly (actual $(1.42) vs $(1.34) estimate)*; YoY EPS loss widened on higher R&D and SG&A tied to pipeline and launch prep .
  • Balance sheet position remains strong ahead of catalysts: ~$1.2B cash, cash equivalents, and marketable securities at 3/31/25; company called remaining ~$570M 0.75% converts (June 6 redemption), implying up to ~17.8M shares if fully converted and lower interest expense going forward .
  • Near‑term catalysts likely to drive stock narrative: Brensocatib PDUFA Aug 12, 2025 (priority review; no AdComm planned) and TPIP PAH Phase 2b topline in June 2025; management aims for a “frictionless” U.S. brensocatib launch if approved .

What Went Well and What Went Wrong

  • What Went Well

    • Broad‑based ARIKAYCE growth: Q1 revenue +22.9% YoY to $92.8M; U.S. +14.1%, Japan +48.3%, Europe/ROW +51.8% YoY, marking the sixth straight quarter of double‑digit growth in each region .
    • Regulatory momentum: FDA priority review for brensocatib with PDUFA 8/12/25; FDA does not currently plan to hold an AdComm; EU/UK filings accepted; Japan filing planned 2025 .
    • Launch readiness and patient activation: >1M unique visits and ~53K self‑identified patients taking high‑value actions on the disease awareness site; payer dialogues constructive, targeting “frictionless launch” .
    • Quote: “Brensocatib’s FDA review process remains on track… we are relentlessly focused on preparing for a frictionless launch” — Will Lewis, CEO .

  • What Went Wrong

    • Loss widened: Net loss $(256.6)M vs $(157.1)M YoY; EPS $(1.42) vs $(1.06) YoY on higher R&D ($152.6M) and SG&A ($147.5M) supporting pipeline and launch prep .
    • Operating loss increased: $(248.1)M vs $(145.5)M YoY; cost of product revenues rose to $21.3M with growth .
    • EPS missed S&P consensus modestly (actual $(1.42) vs $(1.34) estimate); while revenue beat was small (actual $92.8M vs $91.25M estimate) .

Financial Results

MetricQ1 2024Q4 2024Q1 2025
Revenue ($M)$75.5 $104.4 $92.8
Cost of Product Revenues ($M)$17.5 $26.2 $21.3
Operating Loss ($M)$(145.5) $(230.4) $(248.1)
Net Loss ($M)$(157.1) $(235.5) $(256.6)
Diluted EPS ($)$(1.06) $(1.32) $(1.42)

Results vs S&P Global consensus (Q1 2025):

MetricConsensusActualBeat/Miss
Revenue ($M)$91.25*$92.82 Beat
EPS ($)$(1.34)*$(1.42) Miss

Values marked with an asterisk (*) are retrieved from S&P Global.

Segment (Geography) revenue

RegionQ1 2024 ($M)Q1 2025 ($M)YoY Growth
U.S.$56.3 $64.3 14.1%
Japan$14.9 $22.1 48.3%
Europe & ROW$4.3 $6.5 51.8%
Total$75.5 $92.8 22.9%

Balance sheet snapshot

MetricQ4 2024Q1 2025
Cash & Cash Equivalents ($M)$555.0 $403.2
Marketable Securities ($M)$878.8 $796.2
Cash + Marketable Securities (Approx., $B)~$1.43 ~$1.20

Operating drivers / KPIs

KPIQ1 2025
R&D Expense ($M)$152.6
SG&A Expense ($M)$147.5
Cost of Product Revenues as % of Revenues22.9%
2025 ARIKAYCE Revenue Guidance$405–$425M

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Global ARIKAYCE RevenueFY2025$405–$425M (Feb 20, 2025) $405–$425M (May 8, 2025) Maintained
U.S. ARIKAYCE Gross‑to‑NetFY2025n/a“High‑teens to low‑twenties percent” (U.S.) New detail provided

Note: No formal quantitative guidance provided for consolidated margins, OpEx, OI&E, or tax rate. Management reiterated higher OpEx near‑term for launch and pipeline execution .

Earnings Call Themes & Trends

TopicQ3 2024 (Q‑2)Q4 2024 (Q‑1)Q1 2025 (Current)Trend
Brensocatib FDA review & launch prepNDA on track for 4Q24; U.S. launch mid‑2025 expected; deployed 120 reps FDA accepted NDA; Priority Review; PDUFA Aug 12, 2025 Review “on track”; payer engagement; “frictionless launch” objective Building confidence; execution milestones met
Patient funnel & awarenessExpanded sales force focusing on disease awareness —1M+ unique site visits; ~53K self‑identified patients; wide HCP reach Stronger patient/HCP activation
Pricing & Access——Price to be in upper half of $40–96k analog range; early view GTN 25–35% (not formal) Access framework firming pre‑launch
TPIP Phase 2b (PAH)Enrollment ~90% complete; topline 2H25 102 randomized; topline mid‑2025 Topline June 2025; ≥20% PVR reduction = “clear win” Timeline pulled forward; clear success bar
ARIKAYCE growth & ENCOREQ3 rev $93.4M; ENCORE near full enrollment Q4 rev $104.4M; ENCORE topline 1Q26 Q1 rev $92.8M; ENCORE topline 1H26 (Month 15) Durable growth; ENCORE timing clarified
Tariffs & Manufacturing——Minimal tariff exposure (single‑digit $M/yr); expand U.S. manufacturing De‑risking cost base
Gene therapy—INS1201 IND cleared; study 1H25 start Phase 1 initiated; first DMD patient expected 2Q25 Early pipeline advancing

Management Commentary

  • Strategic message: “2025 is off to an exceptionally strong start… ARIKAYCE delivered another quarter of double‑digit year‑over‑year revenue growth… [and] the FDA’s ongoing review of our NDA filing for Brensocatib… remains on track” — Will Lewis, CEO .
  • Launch readiness: “We are relentlessly focused on preparing for a frictionless launch” .
  • TPIP expectations: “If the treatment shows a placebo‑adjusted reduction in PVR of 20%, we would view that as a clear win… 25%… a home run” .
  • Capital and costs: “Approximately $1.2 billion in cash, cash equivalents and marketable securities… tariff impact… single‑digit millions annually” — Sara Bonstein, CFO .

Q&A Highlights

  • Access and pricing: Management reiterated price expectations in upper half of $40–96k analog range and framed early GTN expectation at 25–35% (not formal guidance), with Medicare catastrophic coverage adding ~12% to GTN given ~60% Medicare mix .
  • Patient identification: Definitive diagnosis requires HRCT and pulmonologist assessment; initial target population aligns with ≥2 exacerbations in last 12 months; many undiagnosed patients could emerge post‑approval .
  • Regulatory process: Mid‑cycle review had “no surprises”; inspections to date on schedule; AdComm not currently planned per FDA Day‑74 letter (press release) .
  • TPIP clinical endpoints: PVR prioritized over 6MWD; trial not powered for 6MWD, hoping for 15–20m directional benefit; ~95% of completers entering OLE up to 1,280 μg dose .
  • Tariffs/manufacturing: Minimal tariff exposure due to U.S. IP domiciling; plan to add U.S. brensocatib manufacturing capacity .

Estimates Context

  • Q1 2025 vs S&P Global consensus: Revenue beat by ~$1.6M (actual $92.82M vs $91.25M estimate); EPS slightly missed (actual $(1.42) vs $(1.34) estimate) .
  • Implications: ARIKAYCE demand remains solid; EPS shortfall reflects higher R&D/SG&A tied to launch and pipeline, consistent with management commentary. Near‑term estimate revisions likely minimal for ARIKAYCE; attention should shift to brensocatib pricing/GtN and TPIP efficacy bar, which could have larger model impacts post‑data/approval .
    Values marked with an asterisk (*) are retrieved from S&P Global.

Key Takeaways for Investors

  • ARIKAYCE fundamentals remain healthy with diversified regional growth and FY25 revenue guidance reiterated at $405–$425M, supporting baseline revenue compounding into the brensocatib launch window .
  • Brensocatib remains on track for an 8/12/25 FDA decision (priority review, no AdComm planned), with extensive payer and HCP groundwork positioning for a “frictionless” launch if approved .
  • EPS pressure is deliberate: elevated R&D/SG&A to support launch and pipeline; post‑launch, management expects revenue growth to outpace spend, narrowing operating cash outflows .
  • TPIP June readout is a meaningful upside (or de‑risking) event; ≥20% placebo‑adjusted PVR reduction would be a “clear win,” while once‑daily convenience may amplify clinical utility if efficacy is competitive .
  • Capital structure evolving: called ~$570M converts (June redemption) implying potential dilution (~17.8M shares) but lower interest expense and reduced debt leverage post‑conversion .
  • Watch near‑term narrative drivers: clarity on brensocatib price/GtN and payer criteria; COPD Foundation center build‑out aiding diagnosis/treatment funnel; continued ARIKAYCE growth to fund pipeline .
  • Risk balance: Regulatory execution and access terms for brensocatib, TPIP efficacy risk, and ongoing OpEx scale‑up remain key; balance sheet (~$1.2B liquidity) provides runway through catalysts .
Sources: Q1 2025 8‑K press release and exhibits **[1104506_0001140361-25-017858_ef20048527_ex99-1.htm:0]** **[1104506_0001140361-25-017858_ef20048527_ex99-1.htm:1]** **[1104506_0001140361-25-017858_ef20048527_ex99-1.htm:2]** **[1104506_0001140361-25-017858_ef20048527_ex99-1.htm:3]** **[1104506_0001140361-25-017858_ef20048527_ex99-2.htm:8]**; Q1 2025 earnings call transcript **[1104506_INSM_3426377_1]**–**[1104506_INSM_3426377_23]**; Q4 2024 and Q3 2024 press releases for trend context **[1104506_20250220NY21720:0]**–**[1104506_20250220NY21720:3]** **[1104506_20241031NY44504:0]**–**[1104506_20241031NY44504:2]**; Brensocatib FDA Priority Review and AdComm update press releases **[1104506_20250206NY13009:0]**–**[1104506_20250206NY13009:4]** **[1104506_20250224NY24919:0]**.